Suven Pharmaceuticals Ltd.
|
Income Statement
|
|
You can view the
Income Statement
for the last 5 years.
Market Cap. (Rs.)
|
16793.65 Cr.
|
P/BV
|
9.68
|
Book Value (Rs.)
|
68.16
|
52 Week High/Low (Rs.)
|
768/469
|
FV/ML
|
1/1
|
P/E(X)
|
40.83
|
Bookclosure
|
15/12/2023
|
EPS (Rs.)
|
16.16
|
Div Yield (%)
|
0.00
|
|
(Rs. in Crs.)
Months | 12 | 12 | 12 | 12 | 5 |
Source Of Info (AR = Annual Report, PR = Press Release) | AR | AR | AR | AR | AR |
FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| | | | | |
| | | | | |
INCOME | | | | | |
Revenue From Operations [Net] | 1331.11 | 1307.01 | 995.46 | 817.28 | 369.57 |
Other Operating Revenues | 9.22 | 13.21 | 14.25 | 16.51 | 8.26 |
Total Operating Revenues | 1340.33 | 1320.22 | 1009.72 | 833.79 | 377.83 |
| | | | | |
Other Income | 46.36 | 92.38 | 14.24 | 18.12 | 0.60 |
Total Revenue | 1386.69 | 1412.60 | 1023.96 | 851.91 | 378.43 |
| | | | | |
EXPENSES | | | | | |
Cost Of Materials Consumed | 430.08 | 459.46 | 310.32 | 240.24 | 124.52 |
Operating And Direct Expenses | 176.29 | 173.19 | 122.73 | 105.75 | 51.30 |
Changes In Inventories Of FG,WIP And Stock-In Trade | -20.94 | -60.35 | -8.37 | -11.05 | -21.32 |
Employee Benefit Expenses | 110.51 | 100.48 | 87.29 | 73.72 | 29.63 |
Finance Costs | 5.44 | 6.23 | 9.14 | 23.07 | 2.79 |
Depreciation And Amortisation Expenses | 47.73 | 39.10 | 31.64 | 23.86 | 11.50 |
Other Expenses | 77.86 | 68.02 | 57.27 | 40.02 | 22.15 |
Total Expenses | 826.96 | 786.12 | 610.02 | 495.61 | 220.57 |
| | | | | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 559.73 | 626.48 | 413.94 | 356.30 | 157.87 |
| | | | | |
Profit/Loss Before Tax | 559.73 | 626.48 | 413.94 | 356.30 | 157.87 |
| | | | | |
Tax Expenses-Continued Operations | | | | | |
Current Tax | 146.27 | 190.40 | 101.54 | 88.81 | 33.17 |
Deferred Tax | 4.34 | 23.38 | 3.62 | -1.30 | 15.42 |
Tax For Earlier Years | -2.17 | 0.00 | 0.18 | 0.00 | 0.00 |
Total Tax Expenses | 148.44 | 213.79 | 105.33 | 87.51 | 48.59 |
Profit/Loss After Tax And Before ExtraOrdinary Items | 411.29 | 412.69 | 308.61 | 268.79 | 109.27 |
| | | | | |
Profit/Loss From Continuing Operations | 411.29 | 412.69 | 308.61 | 268.79 | 109.27 |
| | | | | |
Profit/Loss For The Period | 411.29 | 412.69 | 308.61 | 268.79 | 109.27 |
Share Of Profit/Loss Of Associates | 0.00 | 41.11 | 53.74 | 48.21 | 0.00 |
Consolidated Profit/Loss After MI And Associates | 411.29 | 453.80 | 362.34 | 317.00 | 109.27 |
| | | | | |
OTHER INFORMATION | | | | | |
| | | | | |
EARNINGS PER SHARE | | | | | |
Basic EPS (Rs.) | 16.16 | 17.83 | 14.23 | 24.91 | 8.59 |
Diluted EPS (Rs.) | 16.16 | 17.83 | 14.23 | 24.91 | 8.59 |
| | | | | |
DIVIDEND AND DIVIDEND PERCENTAGE | | | | | |
Equity Share Dividend | 203.65 | 101.83 | 25.46 | 63.64 | 19.09 |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 13.08 | 3.92 |